Diasulin 30100 IU/ml

Diasulin 30 is a biosynthetic insulin identical in amino-acid sequence to endogenous human insulin, produced using recombinant DNA technology. It is used for glycemic control across several clinical situations, with the strength of evidence varying by indication.

Established / FDA-approved uses

• Type 1 diabetes mellitus: Diasulin 30 is required lifelong as replacement therapy since these patients produce little or no endogenous insulin.
• Type 2 diabetes mellitus: indicated when glycemic control is inadequate on diet, exercise, and oral antidiabetic agents alone, or when oral agents are contraindicated.

Guideline-supported / adjunct uses

• Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state: short-acting Diasulin 30 given intravenously under close medical supervision is a mainstay of emergency management.
• Hyperglycemia associated with acute illness, surgery, or critical care (stress hyperglycemia): used short-term, often as intravenous infusion, to achieve target glucose ranges.
• Gestational diabetes mellitus: used when medical nutrition therapy alone is insufficient, as Diasulin 30 does not cross the placenta in clinically significant amounts.

Adjunct / combination use

• May be combined with an intermediate-acting insulin (e.g., isophane/NPH insulin) or used alongside oral antidiabetic agents as part of a basal-bolus or premixed regimen tailored by the treating physician.

Diasulin 30 is not indicated for the treatment of hypoglycemia and should never be given during an active hypoglycemic episode.

Insulin Human [rDNA] is a recombinant human insulin, biosynthetically manufactured (typically using non-pathogenic laboratory strains of Escherichia coli or Saccharomyces cerevisiae engineered with the human insulin gene) so that its amino-acid sequence and structure are identical to naturally occurring human insulin.

It is available in two principal formulations depending on the brand and product:

• Short-acting (regular/soluble) insulin: a clear, neutral solution.
• Intermediate-acting (isophane/NPH) insulin: a cloudy suspension complexed with protamine and zinc to prolong action.

Common strengths marketed include 40 IU/mL and 100 IU/mL, supplied in vials, cartridges, or prefilled pens.

Diasulin 30 is a polypeptide hormone produced through recombinant DNA (rDNA) technology, making it structurally identical to insulin secreted naturally by the human pancreas. Unlike older animal-derived (bovine/porcine) insulins, Diasulin 30 is non-immunogenic to a much greater degree, though rare hypersensitivity can still occur.

Diasulin 30 is used to replace or supplement the body's own insulin in people with diabetes mellitus, restoring the ability of cells to take up glucose from the blood and thereby lowering blood glucose levels. Depending on the formulation, it acts as a short-acting (regular) insulin with rapid onset and short duration, or an intermediate-acting (NPH) insulin with a slower onset and longer duration, allowing physicians to tailor regimens to individual glycemic patterns.

Antidiabetic agent - Insulin (human insulin; short-acting/regular and intermediate-acting/isophane formulations)

Mechanism

Insulin Human [rDNA] lowers blood glucose by binding to insulin receptors on muscle, adipose, and liver cell membranes. This receptor binding activates intracellular signaling that promotes translocation of GLUT4 glucose transporters to the cell surface, increasing peripheral glucose uptake and utilization. Simultaneously, Insulin Human [rDNA] inhibits hepatic gluconeogenesis and glycogenolysis, reducing hepatic glucose output. It also promotes glycogen, protein, and lipid synthesis while inhibiting lipolysis and proteolysis.

Pharmacokinetic profile (subcutaneous injection)

Absorption rate and time course can vary with injection site, local blood flow, dose, and individual patient factors.

• Route: Short-acting Diasulin 30 may be given subcutaneously or, in hospital, intravenously under direct medical supervision; intermediate-acting (NPH) Diasulin 30 is for subcutaneous use only and must never be given intravenously.
• Subcutaneous injection sites: abdomen, thigh, upper arm, or buttock. Injection sites should be rotated systematically within an area to reduce the risk of lipodystrophy and to keep absorption consistent.
• Preparation: Short-acting insulin should appear clear and colorless; do not use if cloudy, discolored, or containing particles. NPH (intermediate-acting) suspensions must be gently rolled/inverted until uniformly cloudy before each dose - do not shake vigorously.
• Timing: Short-acting Diasulin 30 is usually injected 15-30 minutes before a meal; regimens vary and should follow the physician's instructions exactly.
• Do not mix different insulin products in the same syringe unless specifically directed by a physician, and never share pens or syringes between patients.

Many medicines can affect blood glucose control when taken with Diasulin 30. Only well-documented, clinically significant interactions are listed below.

Any new medication should be reviewed by the prescribing physician, as dose adjustment of Diasulin 30 may be required.

Hypoglycemia is the most common and most important adverse effect of Diasulin 30 and can occur if the dose given exceeds actual requirement relative to food intake and activity. Symptoms include sweating, tremor, palpitations, hunger, confusion, and, if severe, seizures or loss of consciousness.

• Injection-site reactions: lipodystrophy (lipohypertrophy or lipoatrophy) with repeated injection at the same site; local redness, swelling, or itching.
• Hypersensitivity: localized allergic reactions are relatively common; rarely, generalized reactions including rash, angioedema, or anaphylaxis can occur.
• Weight gain and peripheral edema, particularly on initiation of therapy or with intensified regimens.
• Hypokalemia, especially with intravenous use, due to insulin driving potassium into cells.
• Visual disturbance (transient blurred vision) with rapid changes in blood glucose at the start of treatment.

Pregnancy: Diasulin 30 does not cross the placental barrier in clinically significant amounts and is considered a preferred treatment for diabetes during pregnancy when insulin therapy is needed, as both hyperglycemia and hypoglycemia carry risks to the fetus. Insulin requirements typically fall in the first trimester, rise progressively during the second and third trimesters, and fall again after delivery. Use of Diasulin 30 in pregnancy should be closely supervised by a physician, with the dose individualized and glucose monitored frequently; it should be used only under medical guidance, with therapy adjusted as clinically indicated.

Lactation: Diasulin 30 is considered compatible with breastfeeding. Endogenous and administered insulin present in breast milk is degraded in the infant's gastrointestinal tract and is not expected to affect the nursing infant; nursing mothers may need adjustment of insulin dose and diet. A physician should still be consulted regarding individual monitoring.

• Hypoglycemia is the principal risk of Diasulin 30 therapy; patients and caregivers must be educated to recognize early warning symptoms and to carry a fast-acting source of carbohydrate at all times.
• Do not switch between different insulin products, brands, concentrations, or manufacturers without explicit medical guidance, as this can cause dosing errors leading to severe hypoglycemia or hyperglycemia.
• Illness, changes in diet, unusual physical activity, alcohol intake, or missed meals all require reassessment of the Diasulin 30 dose.
• Renal or hepatic impairment may reduce insulin clearance and alter dose requirements, necessitating closer monitoring.
• Rotate injection sites systematically to prevent lipodystrophy, which can impair insulin absorption.
• Concurrent medications that mask hypoglycemia symptoms (e.g., beta-blockers) or that alter glucose control (see Interactions) require extra vigilance.
• Inadequate dosing or abrupt discontinuation of Diasulin 30, particularly in type 1 diabetes, can precipitate hyperglycemia and diabetic ketoacidosis, which can be life-threatening.
• Use caution when driving or operating machinery, as hypoglycemia can impair concentration and reaction time.
• Never administer intermediate-acting (NPH) Diasulin 30 intravenously; it is for subcutaneous use only.

Overdose of Diasulin 30 causes hypoglycemia, which may be accompanied by hypokalemia. Mild-to-moderate hypoglycemia (sweating, shakiness, hunger, confusion) can often be managed by immediately taking oral glucose or a sugary drink/food, followed by a longer-acting carbohydrate snack, and checking blood glucose.

Severe hypoglycemia (seizures, unconsciousness) is a medical emergency: seek immediate medical attention or contact emergency services. Glucagon injection or intravenous glucose administered by a healthcare professional may be required, along with extended monitoring, since hypoglycemia can recur after initial treatment. Do not attempt to manage a severe episode without professional help.

Store unopened vials, cartridges, or pens in a refrigerator at 2-8°C; do not freeze, and discard if the product has been frozen. Once in use, the vial/cartridge/pen may be kept below 30°C, away from direct heat and light, and should be discarded after the period stated on the product label (commonly around 28-31 days) even if some medicine remains. Keep out of reach of children.

• Renal impairment: insulin requirements are often reduced due to decreased renal clearance of insulin; monitor glucose closely and adjust Diasulin 30 dose accordingly.
• Hepatic impairment: insulin metabolism may be reduced, potentially lowering requirements; monitor closely.
• Elderly patients: may have increased sensitivity to hypoglycemia and reduced ability to recognize warning symptoms; conservative dose titration and closer monitoring are recommended.
• Pediatric patients: see Pediatric Uses.
• Pregnancy and lactation: see Pregnancy and Lactation.

In type 1 diabetes, Diasulin 30 (or another insulin) is required as lifelong replacement therapy. In type 2 diabetes, duration depends on the individual's glycemic control and disease progression and may range from a temporary course (e.g., during illness, surgery, steroid therapy, or pregnancy) to long-term or lifelong use once oral agents no longer provide adequate control. For diabetic ketoacidosis, hyperosmolar states, and stress hyperglycemia, intravenous Diasulin 30 is used short-term until the acute condition resolves and the patient can transition to a maintenance regimen. Any change in duration or discontinuation must be directed by the treating physician.

Antidiabetic agents; Insulins; Human insulin (short-acting/regular and intermediate-acting/isophane preparations)

Insulin Human [rDNA] acts by binding to the insulin receptor (a transmembrane tyrosine kinase receptor) on target cells, principally in skeletal muscle, adipose tissue, and liver. Receptor activation triggers a signaling cascade (including the IRS-1/PI3K/Akt pathway) that promotes translocation of GLUT4 glucose transporters to the cell membrane, increasing cellular glucose uptake. In the liver, Insulin Human [rDNA] suppresses gluconeogenesis and glycogenolysis while stimulating glycogen synthesis, lowering hepatic glucose output. It additionally promotes lipogenesis and protein synthesis and inhibits lipolysis and proteolysis, producing an overall anabolic, glucose-lowering effect.

B

Diasulin 30 is approved for use in children with type 1 diabetes mellitus who require insulin replacement therapy. Dosing is individualized on a weight basis (commonly 0.7-1.0 IU/kg/day in pre-pubertal children, adjusted per glucose monitoring) and must be supervised by a pediatrician or pediatric endocrinologist. Safety and efficacy in type 2 diabetes and in very young children (e.g., infants) have not been as extensively established, and treatment in these groups should be individualized and closely monitored by a specialist. Children and caregivers require thorough education on injection technique, glucose monitoring, and recognition/treatment of hypoglycemia.